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AbstrACt
Objective To assess the value added to the National 
Early Warning Score (NEWS) by mid-regional pro-
adrenomedullin (MR-proADM) blood level in predicting 
deterioration in mild to moderately ill people.
Design Prospective observational study.
setting The Medical Admissions Suite of the Royal 
Victoria Infirmary, Newcastle.
Participants 300 adults with NEWS between 2 and 
5 on admission. Exclusion criteria included receiving 
palliative care, or admitted for social reasons or self-
harming. Patients were enrolled between September 
and December 2015, and followed up for 30 days after 
discharge.
Outcome measure The primary outcome measure was 
the proportion of patients who, within 72 hours, had an 
acuity increase, defined as any combination of an increase 
of at least 2 in the NEWS; transfer to a higher-dependency 
bed or monitored area; death; or for those discharged from 
hospital, readmission for medical reasons.
results NEWS and MR-proADM together predicted acuity 
increase more accurately than NEWS alone, increasing the 
area under the curve (AUC) to 0.61 (95% CI 0.54 to 0.69) 
from 0.55 (95% CI 0.48 to 0.62). When the confounding 
effects of presence of chronic obstructive pulmonary 
disease or heart failure and interaction with MR-proADM 
were included, the prognostic accuracy further increased 
the AUC to 0.69 (95% CI 0.63 to 0.76).
Conclusions MR-proADM is potentially a clinically useful 
biomarker for deterioration in patients admitted to hospital 
with a mild to moderately severe acute illness, that is, with 
NEWS between 2 and 5. As a growing number of National 
Health Service hospitals are routinely recording the NEWS 
on their clinical information systems, further research 
should assess the practicality and use of developing a 
decision aid based on admission NEWS, MR-proADM level, 
and possibly other clinical data and other biomarkers that 
could further improve prognostic accuracy.
IntrODuCtIOn  
The National Early Warning Score (NEWS) is 
recommended for assessing severity of illness 
in patients presenting in primary or secondary 
National Health Service (NHS) care and 
for surveillance of patients in hospital.1 2 
Six physiological parameters (which can be 
measured at the bedside) are scored: respi-
ratory rate, oxygen saturation, temperature, 
systolic blood pressure, pulse rate and level 
of consciousness. The scores are aggregated, 
and, if the patient requires oxygen, the total 
is increased. NEWS predicts death, cardiac 
arrest and unplanned intensive care unit 
(ICU) admission within 24 hours.3–5 However, 
NEWS does not identify all patients who turn 
strengths and limitations of this study
 ► This is the first study to use rigorous statistical 
methods to assess the value added by mid-regional 
pro-adrenomedullin (MR-proADM) to the admission 
National Early Warning Score for predicting clinical-
ly important deterioration in mild to moderately ill 
patients.
 ► Overall prognostic accuracy might have been great-
er had more severely ill patients been included, but 
the aim of this study was to predict deterioration 
in less severely ill patients who could benefit from 
closer observation.
 ► This was an observational study and thus could not 
directly assess the use of more accurate prediction 
of deterioration.
 ► Initial evidence for MR-proADM as a biomarker for 
deterioration appears promising, but requires further 
validation for clinical use.
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out to be seriously ill,6–8 and there are also patients whose 
NEWS is usually elevated and who do not require the 
level of observation that the NEWS tool would suggest. 
For example, people with chronic obstructive pulmonary 
disease (COPD) or chronic heart failure (HF) have higher 
baseline NEWSs than those without these comorbidities. 
The prognostic accuracy of NEWS for patients presenting 
to the emergency department (ED) has been confirmed 
in a wide range of severity of illness,9 10 as has its reduced 
accuracy in people with COPD.11 However, no previous 
studies of the prognostic accuracy of NEWS in the ED/
medical admissions unit (MAU, also called Assessment 
Suite (AS)) have focused on patients admitted with mild 
to moderately severe illness. Since a clinically important 
proportion of these patients do deteriorate unexpectedly, 
improved risk stratification would be useful.
Mid-regional pro-adrenomedullin (MR-proADM) is 
one of several promising biomarkers for severe illness and 
deterioration.12–16
MR-proADM is a precursor of adrenomedullin (ADM), 
a member of the calcitonin peptide family. ADM is widely 
expressed and has roles in vasodilation, immune modula-
tion and metabolic regulation. It is upregulated in severe 
infections, inflammation, vasodilation, stimulation of 
diuresis, increased cardiac output and stroke.17–19 ADM 
has a short half-life, but MR-proADM is more stable and 
directly reflects ADM concentrations in blood. Both ADM 
and MR-proADM levels are strongly associated with risk of 
mortality, regardless of aetiology.20–26 In people presenting 
with acute chest pain, MR-proADM has been reported to 
improve the Global Registry of Acute Coronary Events 
risk classification by 41%.27 As with the NEWS, people 
with COPD or chronic HF have higher baseline levels of 
MR-proADM.
The aim of this study was to assess whether the 
MR-proADM level used alongside the NEWS would 
improve prediction of deterioration over NEWS alone in 
patients admitted to the MAU with mild to moderately 
severe illness.
MethODs
Patient and public involvement
Patients and the public were not specifically involved in 
the planning and execution of this study. However, the 
National Institute for Health Research now requires that 
the research it supports includes active involvement and 
engagement with patients and the public.
study participants and study design
This was a prospective observational cohort study. Patients 
were enrolled between September and December 2015 
at the Royal Victoria Infirmary, Newcastle, and followed 
up for 30 days after discharge. If the patient died within 
30 days of follow-up, this and the cause of death were 
recorded. Adults admitted to the MAU were recruited for 
the study between 9:00 and 16:00 on weekdays.
Sample size was based on a pragmatic recruitment 
target for a 3-month observational study. A recent unpub-
lished audit conducted in the MAU at the Royal Victoria 
Infirmary found a deterioration rate of 20%. With 300 
patients and complete data collection, 60 events would 
be anticipated. With this number of events, a multivari-
able prediction model could include up to six indepen-
dent predictors. This is based on a widely accepted rule of 
thumb that models with fewer than 10 events per predictor 
tend to be overfitted.28 However, recent research suggests 
that the ‘ten events per variable’ rule of thumb may be 
optimistic.29 Because the aim of this study was to assess if 
further research would be indicated, 60 is considered an 
acceptable number of events, even if the rule of thumb is 
optimistic.
Patients were considered eligible for inclusion in the 
study if their NEWS on admission was at least 2 and not 
greater than 5, and all NEWS parameters were recorded. 
Patients were excluded from the study if they were 
receiving palliative care, were admitted for social reasons 
only, or were self-harming, or overdosing with drugs or 
other substances.
recorded data
Demographic and admission data included gender, year 
of birth, reason for admissions, diagnosis on discharge 
and the presence of comorbidities in which baseline 
MR-proADM levels are chronically raised: COPD with 
hypoxia (PaO2 <10 kPa)
7; HF30; acute brain injury6; 
acute coronary syndrome27; acute venous thromboem-
bolism21; high international normalised ratio (>2); acute 
kidney injury; electrolyte disturbances (Na+ <130 or 
>150 mmol/L; K+ <3.0 or >5.5 mmol/L); hyperglycaemia 
in type 1 diabetes (random glucose >10 mmol/L).
The NEWS was assessed at admission and over the 
next 72 hours, and the scores and assessment times were 
recorded. The seven clinical parameters used to deter-
mine the NEWS were recorded for the baseline (admis-
sion) assessment only. Baseline NEWSs were used to 
determine eligibility for this study. Subsequent NEWSs 
were used in the analyses to identify deterioration.
Blood samples were taken at hospital admission for 
assessment of MR-proADM, C reactive protein (CRP) and 
white blood cell (WBC) count.
Laboratory tests
Plasma was obtained from blood samples (collected in 
EDTA) that were no longer clinically required. Plasma 
was stored in aliquots at –80°C.
MR-proADM was assayed in the on-site Blood Sciences 
Laboratory using the B·R·A·H·M·S Kryptor system 
according to the manufacturer’s instructions.
Blood samples were analysed in batches by personnel 
blinded with regard to the condition and NEWS of the 
patient. Nurses who assessed the NEWS and healthcare 
professionals managing patients in the MAU were blinded 
to MR-proADM results.
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Outcome measures
Outcome measure 1: acuity increase
A patient was classified as having an acuity increase if one 
or more of the following occurred within 72 hours from 
admission:
1. Transfer to a higher level of care (ICU or high-depen-
dency unit).
2. Readmission to hospital for reasons related to the ini-
tial admission.
3. Death for reasons related to the initial admission.
4. NEWS increased by at least 2 compared with the ad-
mission score.
Outcome measure 2: deterioration event
For most of the observed acuity increase cases, the reason 
for classification was an increase in the NEWS (table 1). 
An increase in NEWS reflects both measurement varia-
tion and physiological variation, so additional explor-
atory analyses were carried out to assess the performance 
of MR-proADM in predicting deterioration. Deterioration 
events were classified as the occurrence of one or more of 
the following:
1. Transfer to higher level of care within 72 hours from 
admission;
2. Death (for reasons related to the admission) within 30 
days;
3. Readmission to hospital (for the same reason as the pre-
vious admission) within 30 days from first admission.
Classification based on this definition is unlikely to be 
subject to clinically important measurement variation. 
This analysis, therefore, should optimise the prognostic 
accuracy for events which are both clinically and econom-
ically important.
Outcome measure 3: length of stay
Length of stay was defined as the duration (in days) from 
admission to discharge or death.
statistical analysis
All data analyses were performed using the R language, 
V.3.2.0,31 with the support of RStudio, V.0.99.896 
(RStudio). The following R packages were used: ggplot2, 
pROC, psych, PredictABEL, Hmisc and rms.
Logistic regression models were compared for their 
accuracy in predicting deterioration outcome measures 
Table 1 Characteristics of the study population, classified by outcome 1 (acuity increase), outcome 2 (deterioration event) and 
all patients
Outcome 1: acuity increase Outcome 2: deterioration event All patients
(n=292)Present (e=84) Absent Present (e2=32) Absent
Age (mean years, SD) 65 (17) 62 (21) 63 (14) 63 (20) 63 (20)
Gender (no of females, %) 41 (49%) 107 (51%) 15 (47%) 133 (51%) 148 (51%)
NEWS 2 (n, %) 34 (40%) 82 (40%) 12 (38%) 104 (40%) 116 (40%)
NEWS 3 (n, %) 26 (31%) 59 (28%) 9 (28%) 76 (29%) 85 (29%)
NEWS 4 (n, %) 11 (13%) 43 (21%) 4 (13%) 50 (19%) 54 (18%)
NEWS 5 (n, %) 13 (15%) 24 (12%) 7 (22%) 30 (12%) 37 (13%)
MR-proADM (mean nmol/L, 
SD)
1.50 (1.4)
(0.72, 1.12, 1.79)
1.19 (0.9)
(0.68, 0.93, 1.28)
1.89 (2.0)
(0.93, 1.13, 1.95)
1.20 (0.9)
(0.68, 0.93, 1.39)
1.28 (1.1)
(0.68, 0.97, 1.48)
CRP (mg/L) 59 (79)
(5, 22, 80)
42 (70)
(4, 13, 41)
61 (90)
(7, 23, 67)
45 (71)
(4, 16, 51)
47 (73)
(4, 17, 54)
WBC (×109/L) 12 (5)
(9, 10, 14)
11 (5)
(8, 10, 14)
12 (4)
(9, 12, 15)
11 (5)
(8, 10, 14)
11 (5)
(8, 10, 14)
COPD/HF (n, %)* 33 (39%) 46 (22%) 12 (38%) 67 (26%) 79 (28%)
Other comorbidities (n, %) 17 (20%) 55 (26%) 15 (47%) 57 (22%) 72 (25%)
Length of stay (hours) 168 (196)
(63, 110, 194)
137 (176)
(26, 68, 176)
173 (172)
(59, 106, 259)
143 (172)
(33, 72, 176)
146 (182)
(35, 77, 182)
Length of stay in MAU 
(hours)
31 (19)
(17, 25, 43)
24 (16)
(13, 21, 30)
27 (17)
(18, 23, 35)
26 (17)
(15, 22, 31)
26 (17)
(15, 22, 31)
Monitored beds (n, %) 31 (37%) 58 (27%) 11 (34%) 78 (30%) 89 (30%)
Deterioration time (hours) 15 (13)
(5, 9, 21)
NA 170 (226)
(19, 33, 301)
NA
Data are presented as number (n) and percentages (%) for counts, or mean and SD for continuous normally distributed data, 
or (25th, 50th, 75th percentile) for continuous non-normally distributed data. 
*For COPD: e=number with acuity increase, 82; e2=number with deterioration event, 29; n=total number of patients, 282.
COPD, chronic obstructive pulmonary disease; CRP, C reactive protein; HF, heart failure; MAU, medical admissions unit; MR-
proADM, mid-regional pro-adrenomedullin; NA, not applicable; NEWS, National Early Warning Score; WBC, white blood cell.
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as prespecified in an analysis plan. Analyses are presented 
as unadjusted parameter estimates of risk (OR, with CIs) 
and estimates adjusted for identified clinical confounding 
factors. The aims of the multivariable analyses were 
twofold: first, to estimate the effect size and significance 
adjusted for other identified influential predictors and 
interactions; and second, to investigate whether the addi-
tion of other predictors improved the goodness of fit and 
accuracy of prediction.
Only complete cases were analysed since missingness 
was minimal: 10 records without data on comorbidities 
(details in footnote in table 1).
For each measure of deterioration (acuity increase, 
deterioration event and length of stay), logistic regression 
models were compared for the following sets of predictor 
variables:
Predictor set a. Comparator (base case): NEWS on 
admission.
Predictor set b. Primary analysis: NEWS, MR-proADM.
Predictor set c. Secondary analyses: NEWS and 
MR-proADM always included. Age, gender, CRP, WBC, 
presence of COPD or HF, presence of other comorbidities 
and interactions between predictors when appropriate.
Predictors (and the underlying assumption of linearity 
of their relationship with the outcome of interest) were 
initially investigated through univariate analyses based on 
simple log and quadratic functions. Transformations were 
applied if they improved the goodness of fit as assessed 
by the Akaike information criterion (AIC) and were 
retained in the multivariable setting. NEWS was treated 
as an ordinal variable. We assessed interactions through 
visual data exploration without significance testing as 
the study was not powered for this. For the multivariable 
regression models, the set of predictors was assessed for 
independence through backward elimination, based on 
changes in AIC.
The analysis plan for the secondary outcome of length 
of stay was similar: using multiple linear regressions 
based on transformed outcomes to address non-nor-
mality. Dependent and exploratory variables were 
log-transformed if not normally distributed. Normality 
was assessed by visualising the data. More details on the 
methods used are reported in online supplementary 
material 1.
Goodness of fit of logistic regression models was 
assessed with the C-statistic (which is the area under the 
receiver operating characteristic curve and is used as 
a measure of discrimination) presented with 95% CIs. 
To assess the value added by including the MR-proADM 
level with the NEWS in predicting deterioration, 
continuous net reclassification improvement (NRI) 
and integrated discrimination improvement (IDI) were 
calculated.32 33
For internal validation of the statistical models, the 
C-statistic was evaluated after correcting for optimistic 
predictions through bootstrapping with 10 000 resamples.
resuLts
study enrolment
The process of recruitment and enrolment of patients 
for the study is shown in figure 1. The study recruited 
300 patients, and 292 were included in the analysis. Five 
patients were excluded because the blood samples for 
MR-proADM were taken more than 12 hours from base-
line NEWS assessment; three patients were excluded from 
the primary outcome due to missing follow-up NEWSs.
Patient characteristics
Patient demographics and mean biomarker levels for 
each covariate are reported in table 1. The cohort was 
evenly divided in gender and had a mean age of 63 years 
and mean NEWS on admission of 3, with the majority of 
patients having NEWS of 2. COPD or HF was present in 
28%, and 25% had other comorbidities.
The study population was homogeneous across acuity 
increase and no acuity increase outcomes in terms of gender, 
age and NEWS on admission. Table 2 shows the frequen-
cies of criteria determining acuity increase and deterioration 
event. Notably, around 95% of acuity increases were the 
result of an increase in NEWS, while readmission was the 
reason for around 70% of deterioration events.
Patients who experienced acuity increase had higher 
MR-proADM and CRP levels at admission, and longer 
length of stay in the hospital and in the MAU.
The prevalence of acuity increase was 29% (somewhat 
higher than the anticipated 20%). The prevalence of dete-
rioration events was 11%. The numbers of events provided 
sufficient statistical power to assess statistical significance 
for the primary outcome, acuity increase, but not for the 
secondary outcome, deterioration event.
Accuracy of Mr-proADM for predicting acuity increase
Potentially useful predictors with univariate analysis of 
acuity increase were MR-proADM (OR 1.27, 95% CI 1.02 
to 1.62; p=0.037), age2 (OR 1.00, 95% CI 0.99 to 1.00; 
p=0.023) and the presence of COPD or HF (OR 2.25, 
95% CI 1.30 to 3.91; p=0.004; online supplementary figure 
S1). The prognostic accuracy of CRP, WBC and NEWS did 
not reach the threshold of significance (p=0.88, p=0.090, 
table 3, and p=0.416, table 4, respectively).
The prognostic accuracy for acuity increase of NEWS 
on its own was limited and not significant (area under 
the curve (AUC) 0.55, 95% CI 0.48 to 0.62), but when 
MR-proADM was included as an additional predictor, the 
accuracy of the model increased (AUC 0.61, 95% CI 0.54 
to 0.69; OR 1.28, 95% CI 1.02 to 1.63; p=0.039) (tables 4 
and 5, figure 2A). When including MR-proADM with 
NEWS, the reclassification of patients was also signifi-
cant, especially for the NRI (NRI 0.3, SE 0.1, p=0.007, IDI 
0.017; table 4).
The prognostic accuracy of MR-proADM and the addi-
tional value it provides to the NEWS was confirmed for 
deterioration events and length of stay (tables 4 and 5, and 
figure 2B,C).
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For MR-proADM alone, the AUCs were for acuity 
increase 0.58 (0.51 to 0.66) and deterioration event 0.64 (0.54 
to 0.74). For length of stay, the R2 was 0.12.
effect on prognostic accuracy when clinical information is 
added to the set of predictors
Secondary multivariable modelling evaluated the prog-
nostic accuracy of MR-proADM when adjusted for the 
clinical factors in predictive set c: age, gender, CRP, 
WBC, presence of COPD or HF, and presence of other 
comorbidities,
For acuity increase, COPD or HF comorbidity status and 
its interaction with MR-proADM level improved the prog-
nostic accuracy of the model: AUC increased from 0.61 
(95% CI 0.54 to 0.69) to 0.69 (95% CI 0.63 to 0.76) and 
net reclassification index from 0.3 to 0.4 (table 5).
For deterioration events, the presence of other comor-
bidities (excluding COPD and HF) and age2 increased 
the prognostic accuracy of MR-proADM (tables 4 and 
5). The prognostic accuracy of length of stay (outcome 3) 
of MR-proADM is also increased by including age in the 
model (tables 4 and 5, online supplementary figure S2).
Potential confounding effects
Shorter-term outcomes
NEWS and MR-proADM were less accurate in predicting 
acuity increase within 24 and 12 hours from admission 
than in predicting acuity increase within 72 hours (online 
supplementary table S1 and S2).
Table 2 Criteria met by patients classified with an acuity 
increase or deterioration event
Criterion for 
deterioration
Acuity increase
(e=84)
Deterioration event
(e2=32)
NEWS (n, %) 81 (96.4%) NA
ICU transfer (n, %) 1 (1.2%) 4 (12.5%)
Death (n, %) 0 (0%) 6 (18.8%)
Readmission (n, %) 2 (2.4%) 22 (68.7%)
ICU, intensive care unit; NA, not applicable; NEWS, National Early 
Warning Score.
Figure 1 Patient recruitment process. AS, Assessment Suite, also called as Medical Admissions Unit (MAU); GP, general 
practitioner; MR-proADM, mid-regional pro-adrenomedullin; NEWS, National Early Warning Score.
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Interval between admission NEWS scoring and blood collection
Because ward processes did not allow the times of scoring 
NEWS and collecting blood to be specified for research, 
we assessed for a confounding effect from variation in the 
timings, but found no evidence for it (online supplemen-
tary table S3).
Correlations among biomarkers
Diagnostic plots, shown in online supplementary figure 
S1 and S3, show no multicollinearity in the data, no auto-
correlation, no heteroscedasticity and no data points that 
stood out in terms of their influence on results.
sensitivity and specificity
As overall measures of accuracy, sensitivity and specificity 
were calculated (where appropriate) for each model using 
Youden’s index. The results are shown in online supple-
mentary table S4. In practice, the trade-off between sensi-
tivity and specificity would depend on the type of clinical 
decision to be made on the result (ie, ‘rule-in’ or ‘rule 
out’) and this would differ from the approach in Youd-
en’s Index, which gives equal weight to false-positive and 
false-negative results.
Internal validation
C-statistic values after correcting for optimistic predic-
tions (ie, bootstrapped average of the AUC for each 
model) were as follows: for acuity increase—predictor 
set a, C-stat 0.53; predictor set b, C-stat 0.59; predictor 
set c, C-stat 0.66; for deterioration events—predictor set a, 
C-stat 0.52; predictor set b, C-stat 0.61; predictor set c, 
Table 3 Univariate regression analyses for predicting the three outcomes of interest: acuity increase, deterioration event and 
length of stay
Beta CI OR (CI) P values
Acuity increase: univariate logistic regressions (n=292, e=84)
  MR-proADM 0.24 −0.02 to 0.48 1.27 (1.02 to 1.62) 0.037
  CRP 0.003 −0.0005 to 0.0063 1.00 (1.00 to 1.01) 0.088
  WBC 0.04 −0.008 to 0.094 1.05 (1.00 to 1.10) 0.09
  Gender 0.14 −0.38 to 0.65 1.15 (0.69 to 1.92) 0.684
  Age 0.1 0.019 to 0.1925 1.11 (1.02 to 1.21) 0.023
  Age2 −0.0008 −0.0016 to 0.0001 1.00 (0.99 to 1.00)
  Other comorbidities −0.32 −0.96 to 0.28 0.72 (0.38 to 1.32) 0.267
  COPD/HF* 0.81 0.26 to 1.36 2.25 (1.30 to 3.91) 0.004
Deterioration event: univariate logistic regressions (n=292, e2=32)
  MR-proADM 0.37 0.11 to 0.64 1.44 (1.12 to 1.90) 0.006
  CRP 0.003 −0.002 to 0.01 1.00 (1.00 to 1.01) 0.255
  WBC 0.02 −0.05 to 0.09 1.02 (0.95 to 1.10) 0.506
  Gender 0.17 −0.57 to 0.92 1.19 (0.57 to 2.50) 0.648
  Age 0.21 0.06 to 0.40 1.23 (1.06 to 1.49) 0.013
  Age2 −0.002 −0.003 to 0.001 1.00 (1.00 to 1.00)
  Other comorbidities 1.14 0.38 to 1.90 3.14 (1.47 to 6.69) 0.003
  COPD/HF* 0.67 −0.14 to 1.46 1.96 (0.87 to 4.29) 0.095
Length of stay: simple linear regressions (n=292, e=84, e2=32)
  MR-proADM 0.7 0.49 to 0.92 NA <0.0001
  CRP 0.05 −0.05 to 0.15 NA 0.368
  WBC −0.06 −0.38 to 0.27 NA 0.73
  Gender 0.08 −0.04 to 0.20 NA 0.18
  Age 0.007 0.004 to 0.010 NA <0.0001
  Other comorbidities 0.18 0.05 to 0.32 NA 0.009
  COPD/HF* 0.07 −0.07 to 0.21 NA 0.318
The p values are for the statistical significance of the corresponding covariate in the related model. Analyses for the NEWS as a predictor are 
shown in Table 4. 
*n=282, e=82, e2=29.
 COPD, chronic obstructive pulmonary disease; CRP, C reactive protein; e, number of acuity increases; e2,number of deterioration events; 
HF, heart failure; MR-proADM, mid-regional pro-adrenomedullin; n, total number of cases; NA, not applicable; NEWS, National Early Warning 
Score; WBC, white blood cell.
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Table 4 Multivariable regression analyses for the outcomes of interest: acuity increase, deterioration event and length of stay 
(outcomes 1, 2 and 3, respectively) with NEWS comparator group
Beta CI OR (CI) P values
Acuity increase: multivariate logistic regressions
Predictor set a
n=292 e=84 e2=32
NEWS 3 0.06 −0.55 to 0.67 1.06 (0.57 to 1.95) 0.416
NEWS 4 −0.48 −1.29 to 0.27 0.62 (0.27 to 1.31)
NEWS 5 0.27 −0.54 to 1.04 1.31 (0.58 to 2.84)
Predictor set b
n=292 e=84 e2=32
NEWS 3 0.03 −0.59 to 0.65 1.03 (0.56 to 1.91) 0.247
NEWS 4 −0.53 −1.35 to 0.23 0.59 (0.26 to 1.26)
NEWS 5 0.18 −0.63 to 0.97 1.20 (0.53 to 2.64)
MR-proADM 0.24 0.02 to 0.49 1.28 (1.02 to 1.63) 0.039
Predictor set c
n=282 e=82 e2=29
NEWS 3 −0.11 −0.76 to 0.54 0.90 (0.47 to 1.71) 0.221
NEWS 4 −0.89 −1.77 to 0.08 0.41 (0.17 to 0.93)
NEWS 5 0.09 −0.77 to 0.91 1.09 (0.46 to 2.50)
MR-proADM 0.41 0.13 to 0.76 1.51 (1.14 to 2.14) 0.01
COPD/HF 1.81 0.80 to 2.85 6.08 (2.23 to 17.35) 0.001
MR-proADM×COPD/HF −0.71 −1.40 to 0.10 0.49 (0.25 to 0.91) 0.03
Deterioration event: multivariate logistic regressions
Predictor set a
n=292 e=84 e2=32
NEWS 3 0.03 −0.92 to 0.94 1.03 (0.40 to 2.55) 0.512
NEWS 4 −0.37 −1.68 to 0.74 0.69 (0.19 to 2.10)
NEWS 5 0.7 −0.36 to 1.70 2.02 (0.70 to 5.50)
Predictor set b
n=292 e=84 e2=32
NEWS 3 −0.01 −0.97 to 0.92 0.99 (0.38 to 2.51) 0.564
NEWS 4 −0.43 −1.76 to 0.70 0.65 (0.17 to 2.02)
NEWS 5 0.6 −0.49 to 1.62 1.81 (0.61 to 5.05)
MR-proADM 0.36 0.10 to 0.64 1.43 (1.11 to 1.89) 0.007
Predictor set c
n=282 e=82 e2=29
NEWS 3 0.16 −0.83 to 1.12 1.17 (0.44 to 3.07) 0.389
NEWS 4 −0.49 −1.86 to 0.69 0.62 (0.16 to 2.00)
NEWS 5 0.69 −0.44 to 1.76 1.99 (0.64 to 5.81)
MR-proADM 0.32 0.02 to 0.64 1.37 (1.02 to 1.89) 0.044
Other comorbidities 0.94 0.10 to 1.77 2.56 (1.10 to 5.85) 0.026
Age 0.21 0.06 to 0.41 1.23 (1.06 to 1.50) 0.011
Age2 −0.002 −0.003 to 0.001 1.00 (1.00 to 1.00)
Length of stay: multiple linear regressions
Predictor set a
n=292 e=84 e2=32
NEWS 3 −0.07 −0.21 to 0.08 NA 0.052
NEWS 4 0.07 −0.10 to 0.24 NA
NEWS 5 0.21 0.01 to 0.40 NA
Predictor set b
n=292 e=84 e2=32
NEWS 3 −0.1 −0.24 to 0.04 NA 0.033
NEWS 4 0.05 −0.11 to 0.21 NA
NEWS 5 0.14 −0.04 to 0.32 NA
MR-proADM 0.69 0.48 to 0.91 NA <0.0001
Predictor set c
n=282 e=82 e2=29
NEWS 3 −0.12 −0.25 to 0.02 NA 0.031
NEWS 4 0.04 −0.11 to 0.20 NA
NEWS 5 0.14 −0.04 to 0.32 NA
MR-proADM 0.55 0.31 to 0.80 NA <0.0001
Age 0.004 0 to 0.007 NA 0.027
 Predictor set a includes only the NEWS as a predictor. Predictor set b includes MR-proADM and NEWSs. Predictor set c includes 
MR-proADM, NEWSs and other significant predictors and interactions. The p values are for the statistical significance of the 
corresponding covariate in the related model.
COPD, chronic obstructive pulmonary disease; HF, heart failure; MR-proADM, mid-regional pro-adrenomedullin; NA, not applicable; 
NEWS, National Early Warning Score.
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C-stat 0.68; for length of stay— predictor set a, R2=0.003; 
predictor set b, R2=0.12; predictor set c, R2=0.13. AUCs 
decreased slightly with the bootstrapped averages, but the 
differences between the AUCs for predictor sets a, b and 
c were constant. These results are an internal validation, 
and further validation on an external dataset is required.
DIsCussIOn
Accuracy of prediction of deterioration by Mr-proADM
This study shows that MR-proADM may be a clinically 
useful biomarker for predicting deterioration (ie, acuity 
increase) within 72 hours from admission to hospital in 
mild to moderately ill patients with admission NEWS 
Table 5 Model comparisons
AIC Deviance
AUC (CI) or
R2 for linear 
regression LR (df), p value NRI (SE), p value IDI (SE), p value
Acuity increase: logistic regressions
Outcome 1—predictor set a 348 356 0.55 (0.48 to 0.62)
Outcome 1—predictor set b 343 353 0.61 (0.54 to 0.69) 5 (1), 0.033 0.3 (0.1), 0.007 0.017 (0.009), 
0.058
Outcome 1—predictor set c 317 331 0.69 (0.63 to 0.76) 14 (2), 0.001* 0.4 (0.1), 0.0004* 0.05 (0.01), 
0.0009*
Deterioration event: logistic regressions
Outcome 2—predictor set a 199 207 0.57 (0.47 to 0.68)
Outcome 2—predictor set b 192 202 0.65 (0.54 to 0.76) 7 (1), 0.007 0.4 (0.2), 0.003 0.04 (0.02), 0.10
Outcome 2—predictor set c 177 193 0.73 (0.63 to 0.84) 15 (3), 0.0019* 0.5 (0.2), 0.012* 0.06 (0.02), 
0.0004*
Length of stay: linear regressions (LR)
Outcome 3—predictor set a 77 −381 0.03
Outcome 3—predictor set b 68 −417 0.14 9 (1), <0.001
Outcome 3—predictor set c 67 −420 0.16 1 (1), 0.026
Outcomes 1, 2 and 3 refer to acuity increase, deterioration event and length of stay, respectively. The predictors are set a, NEWS alone; set b, 
NEWS and MR-proADM; and set c, NEWS, MR-proADM and other significant predictors and interactions detailed in Table 3.
*Comparison is between predictor set b and c. Since there was a mismatch between the cases for predictor set a and b (10 missing values in 
chronic obstructive pulmonary disease/heart failure), in the model with predictors set b, the 10 cases missing in predictor set c were dropped 
to allow the comparison.
AIC, Akaike information criterion; AUC, area under the receiver operating characteristic curve; IDI, integrated discrimination improvement; LR, 
likelihood ratio; MR-proADM, mid-regional pro-adrenomedullin; NEWS, National Early Warning Score; NRI, net reclassification improvement.
Figure 2 (A) Prognostic accuracy for acuity increase. Predictor set a: NEWS; predictor set b: NEWS, MR-proADM; predictor 
set c: NEWS, MR-proADM, COPD/HF, interaction between MR-proADM and COPD/HF. (B) Comparisons as for panel (A) but 
for predicting a deterioration event. Predictor set c: NEWS, MR-proADM level, age2, other comorbidities. (C) Length of stay 
predicted by MR-proADM level. COPD, chronic obstructive pulmonary disease; HF, heart failure; MR-proADM, mid-regional pro-
adrenomedullin; NEWS, National Early Warning Score. 
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between 2 and 5. By design, NEWSs in this range imply 
a low risk of deterioration, and our data are consistent 
with this. Previous evaluations of the NEWS assessed on 
admission have found that it predicts deterioration,3–5 34 
which may seem inconsistent. But these studies included 
all patients admitted to ED, whatever their NEWS.
For most of the observed acuity increase events, the 
reason for classification was an increase in the NEWS. 
Because an increase in NEWS reflects both measurement 
variation and physiological variation, additional explor-
atory analyses were carried out to assess the performance 
of MR-proADM, using an operational definition of deteri-
oration, deterioration event, designed to minimise measure-
ment variation. NEWS on its own had low prognostic 
accuracy for deterioration events. However, MR-proADM 
level and NEWS together predicted deterioration events 
with an AUC of 0.65. Considering baseline patient char-
acteristics further increased the accuracy of the model 
(AUC=0.73).
Comorbidities and interactions with Mr-proADM levels
MR-proADM levels in people with COPD and/or HF 
are chronically raised and are not predictive of deteri-
oration. However, in other people whose MR-proADM 
levels are not chronically raised, high levels are predic-
tive of acuity increase (online supplementary figure S1). 
Including these comorbidities and their interaction with 
MR-proADM level increased the prognostic accuracy of 
the logistic regression model.
Limitations
This study included only patients who were admitted with 
a NEWS between 2 and 5. The prognostic accuracy of the 
MR-proADM would perhaps have been greater if more 
extreme cases had been included. However, patients with 
NEWSs more than 5 are already known to be severely ill 
and to require close monitoring and/or management at 
higher levels of care.
Internal validation found that the uncorrected C-statis-
tics are optimistic, which implies that external validation 
in an independent study would be useful. However, after 
correction for optimistic predictions, the study’s conclu-
sions remain unchanged.
Interpretations and implications
The contributions of MR-proADM to the accuracy of the 
prognostic models suggests that it could provide addi-
tional prognostic information over and above NEWS.
Secondary analyses suggest that a potentially useful 
clinical decision aid could be based on the NEWS, 
MR-proADM level and clinical features.
Future research and development
As a growing number of NHS hospitals are implementing 
the NEWS on their clinical information systems, it should 
be practical to develop a decision aid based on admission 
NEWS, MR-proADM level and clinical features. Other 
biomarkers may further improve prognostic accuracy 
for deterioration, for example, lactate,3 peroxiredoxin-4 
and copeptin,22 35 36 and soluble urokinase plasminogen 
activator receptor.37 The feasibility, cost-effectiveness and 
acceptability of such decision aids needs to be evaluated 
in further research.
A rapid point-of-care test for MR-proADM could facili-
tate the assessment process and reduce delays in arranging 
optimal levels of care and intensity of monitoring. Future 
research could identify the threshold MR-proADM level 
corresponding to the optimal combination of sensitivity 
and specificity for a binary test (eg, ‘present’ or ‘absent’) 
for deterioration.
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